Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

• Status: Completed
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the role of the pulmonary vasculature in the development and progression of chronic obstructive pulmonary disease (COPD). To accomplish this, an inhaled prostacyclin (iloprost) will be given to patients with COPD and changes in oxidative stress and lung volumes during exercise will be measured.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Louisiana State University Health Sciences Center in New Orleans
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• 40 years old or older

• Physician diagnosis of chronic obstructive pulmonary disease

• 10 or more pack-year smoking history

• FEV1/FVC <0.70

• FEV1 35-80% of predicted

Exclusion Criteria:

• Acute exacerbation of COPD within the last 30 days

• Pregnant or breast-feeding

• Contraindications to cardiopulmonary exercise testing

• Known intolerance or allergy to iloprost

• On oral corticosteroids (may be included if off for 7 days prior to testing)

• Supplemental oxygen need

• Known inflammatory disease other than COPD

• Active solid organ/hematologic malignancy